RxLink’s Post

Access to essential medications is a fundamental pillar of improved patient outcomes. With negotiated prices for 10 critical drugs set to take effect in 2026, Medicare recipients are poised to see out-of-pocket costs drop by up to 79%, bringing much-needed relief to millions. This pivotal initiative is not only a victory for affordability but also for equity in healthcare, ensuring life-saving treatments are within reach for all. By bridging the gap between cost and care, we are moving one step closer to a healthcare system that truly serves its people—because no one should have to choose between their health and financial security. An insightful article on Medicare drug price negotiations by Fast Company. #AffordableCare #AccessibilitytoEssentialMedication #HealthEquity #PatientOutcomes #MedicationManagement

Employers and health plans are noticing high discontinuation rates of GLP-1 weight-loss medications. These effective drugs often see a significant drop-off, with 30% of users stopping in the first month, mostly due to GI discomfort, according to a recent analysis by Blue Health Intelligence. At Digbi Health, weight management is more than just medication. That's why we created the only #GLP-1 weight-loss program that integrates #digestivehealth care. Our approach helps your employees manage their weight while addressing gut health issues.   * A large health trust managing benefits for municipal employees and teachers' unions, in partnership with their health plan and PBM, selected Digbi Health's Precision biology-based GLP program to ensure the cost-effectiveness and adherence to these medications.* Using our patented GLP Compass tool, the Digbi program has already improved adherence by 60% and reduced GLP costs by 41%. Mercer WTW Aon Business Group on Health Solera Health Blue Shield of California Aetna, a CVS Health Company

✨ To address the ongoing challenges surrounding the shortage of GLP-1 medications, Ro, a direct-to-patient healthcare company, has launched the GLP-1 Supply Tracker, an innovative tool designed to provide patients with real-time insights and automated alerts on GLP-1 drug availability. The GLP-1 shortage — which has impacted access to popular weight loss and diabetes management drugs like Wegovy and Ozempic — has left many patients scrambling to find their necessary medications. Ro's new GLP-1 Supply Tracker aims to alleviate this burden by empowering patients with the information they need. #HealthcareInnovation #HealthTech #GLP1 #PatientCare #MedicationManagement #HealthSolutions #DigitalHealth #WellnessJourney #MedicalAdvancements #HealthAwareness #PharmacyLife #MedicalUpdates

It’s disappointing that the Federal government has decided to not take forward a recommendation from a standing committee on Health and Aged care to allow pharmacists to prescribe COVID anti-virals. Allowing pharmacists to prescribe the anti-virals would only be following successful steps taken in other comparable countries such as: New Zealand, the United States and parts of Canada that has increased patient access for timely start of treatment. These treatments are often very effective but must be commenced within 5 days of symptoms appearing - and sometimes patients can have challenges accessing Telehealth appointments with GPs. Feedback from pharmacies that service residential aged care has been they’ve received large quantities of expired anti virals returned for destruction as they were given a stock pile. Whilst loading up aged care with stock had the best of intentions it has resulted in significant waste in some instances. Allowing pharmacists to prescribe would have proven to be another access point to offer timely, efficient access to treatment. We need to work smarter not just harder in our health system and allowing pharmacists to work to full scope is part of the solution for a stretched health system and for patient benefit.

Keywords: FOLLOW-UP, CHANGING PATIENT BEHAVIOR, DON'T QUIT - TRUST THE PROCESS. The lack of this may lead to limited results or the failure of any surgical or nonsurgical approach. Remember: Staplers, Ellipses Balloon, and GLP-1 weight loss drugs are tools with great results when the patient follows up. It is good to mention contacting the doctor to learn about the potential side effects of GLP-1 weight loss drugs. Remember, it is your body and your money; decide for the best.

Breaking barriers in healthcare: F.T.C. takes aim at drug middlemen to lower skyrocketing insulin prices for all. #HealthcareReform #LowerInsulinPrices #DrugPricing #FTCAction #PatientAdvocacy #AccessToMedicine #NewYork #NYC

GLP-1 medications play a crucial role in managing diabetes and weight-related conditions and have been in the news recently given their high price tag and the impact on coverage and affordability. Read Truveris’ latest news roundup to stay up to date on the GLP-1 landscape. #PharmacyBenefits #SpecialtyDrugs #PBM #Truveris

We as consumers are inundated daily with ads about all of the GLP-1 drugs that are on the market. This means that that employees expect their employers to give them access to these drugs. So...how can you better evaluate the place of GLP-1s and ensure optimization? Do the results outweigh the costs? Join EPIC Insurance Brokers & Consultants on August 22nd to learn more about how you can create a path that illuminates when GLP-1s are the right choice for treatment, and strategies for smart utilization. #EmployeeBenefits #BenefitsCurve #CostContainment #PharmacyStrategy #GLP1 #Obesity #DiabetesType2 #EPICness

The FTC brought action against the top PBMs — CVS Health's Caremark Rx, Cigna's Express Scripts, and United Health Group's OptumRx — saying the companies created a "perverse drug rebate system" that artificially inflates the cost of insulin.This rebate schemes, according to the FTC, contributed to inflated costs for patients while the companies collected billions in rebates and fees and keeping lower - cost options off their approved drig list. The FTC claims this has limited more affordable choices for consumers and increased out-of-pocket expenses for essential diabetes medications. #FTC #CVSHealthsCaremarkRx #Cigna #UnitedHealthCare #UnitedHealthGroupOptumRx #CignaExpressScripts

Are GLP-1 drugs the future of diabetes treatment? Dive into the latest insights and trends in this MedCity News article. Discover what experts, like our own Nicole Bulochnik, are saying about the sustainability and impact of GLP-1 drugs on the healthcare industry. Click the link to learn more! #HealthCareInnovation #DiabetesTreatment #GLP1Drugs